Literature DB >> 12397841

The Duke Somatic Treatment Algorithm for Geriatric Depression (STAGED) approach.

David C Steffens1, Douglas R McQuoid, K Ranga Rama Krishnan.   

Abstract

Although there have been previously published algorithms for the treatment of depression, few have been rigorously studied in terms of outcome. We present the Duke Somatic Treatment Algorithm for Geriatric Depression (STAGED) approach, developed by clinicians in the Duke Mood Disorders Program. The algorithm consists of five stages based on treatment history. In developing the approach, we enrolled 228 depressed elderly patients in a National Institute of Mental Health-funded longitudinal study of depression. Patients were treated by geriatric psychiatrists using the algorithm as a guideline for treatment. Initially, 174 patients were treated with antidepressant medications, and 54 patients were treated with electroconvulsive therapy. Over the course of 18 months of treatment, 88.6% of patients responded, and 65.35% of patients were able to achieve full remission of symptoms. The STAGED approach appears to be a clinically useful method of successfully treating elderly depressed patients.

Entities:  

Mesh:

Year:  2002        PMID: 12397841

Source DB:  PubMed          Journal:  Psychopharmacol Bull        ISSN: 0048-5764


  43 in total

1.  Methodology and preliminary results from the neurobiology of late-life depression study.

Authors:  David C Steffens; Kevin J Manning; Rong Wu; James J Grady; Richard H Fortinsky; Howard A Tennen
Journal:  Int Psychogeriatr       Date:  2015-09-01       Impact factor: 3.878

2.  Association of attentional shift and reversal learning to functional deficits in geriatric depression.

Authors:  Guy G Potter; Douglas R McQuoid; Martha E Payne; Warren D Taylor; David C Steffens
Journal:  Int J Geriatr Psychiatry       Date:  2012-01-24       Impact factor: 3.485

3.  Outcomes of older cognitively impaired individuals with current and past depression in the NCODE study.

Authors:  David C Steffens; Douglas R McQuoid; Guy G Potter
Journal:  J Geriatr Psychiatry Neurol       Date:  2009-02-04       Impact factor: 2.680

4.  Comorbid chronic illness and the diagnosis and treatment of depression in safety net primary care settings.

Authors:  Chizobam Ani; Mohsen Bazargan; David Hindman; Douglas Bell; Michael Rodriguez; Richard S Baker
Journal:  J Am Board Fam Med       Date:  2009 Mar-Apr       Impact factor: 2.657

5.  Neurocognitive correlates of response to treatment in late-life depression.

Authors:  Tyler J Story; Guy G Potter; Deborah K Attix; Kathleen A Welsh-Bohmer; David C Steffens
Journal:  Am J Geriatr Psychiatry       Date:  2008-08-12       Impact factor: 4.105

6.  Change in stress and social support as predictors of cognitive decline in older adults with and without depression.

Authors:  Whitney J Dickinson; Guy G Potter; Celia F Hybels; Douglas R McQuoid; David C Steffens
Journal:  Int J Geriatr Psychiatry       Date:  2011-03-02       Impact factor: 3.485

7.  Biochemical abnormalities of the medial temporal lobe and medial prefrontal cortex in late-life depression.

Authors:  Talaignair N Venkatraman; Ranga R Krishnan; David C Steffens; Allen W Song; Warren D Taylor
Journal:  Psychiatry Res       Date:  2009-04-30       Impact factor: 3.222

8.  Reduced comparison speed during visual search in late life depression.

Authors:  Guy G Potter; David J Madden; Mathew C Costello; David C Steffens
Journal:  J Clin Exp Neuropsychol       Date:  2013-11-13       Impact factor: 2.475

9.  The COMT Val158Met polymorphism and cognition in depressed and nondepressed older adults.

Authors:  G G Potter; W D Taylor; D R McQuoid; D C Steffens; K A Welsh-Bohmer; K R R Krishnan
Journal:  Int J Geriatr Psychiatry       Date:  2009-10       Impact factor: 3.485

10.  Angiotensin receptor gene polymorphisms and 2-year change in hyperintense lesion volume in men.

Authors:  W D Taylor; D C Steffens; A Ashley-Koch; M E Payne; J R MacFall; C F Potocky; K R R Krishnan
Journal:  Mol Psychiatry       Date:  2009-03-10       Impact factor: 15.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.